

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Endurance RP Limited

壽康集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 575)

Profit Warning

This announcement is made by Endurance RP Limited (the “**Company**” and collectively with its subsidiaries, the “**Group**”) in compliance with the disclosure requirements under Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders and potential investors of the Company that based on the preliminary assessment of the unaudited consolidated management accounts of the Group and the information currently available, the Group expects to record a loss attributable to the equity holders of the Company for the period ended 30 June 2022 (the “**Reporting Period**”) of between approximately US\$20 million (or approximately HK\$156 million) to approximately US\$23 million (or approximately HK\$179.40 million), which represents a loss as compared to a profit attributable to the equity holders of the Company of approximately US\$2.66 million (or approximately HK\$20.75 million) for the period ended 30 June 2021 (the “**Corresponding Period**”).

The above-mentioned negative change in the unaudited consolidated interim results for the Reporting Period as compared to the Corresponding Period is mainly attributable to:

- i) the Group recording realised and an unrealised marked-to-market losses of approximately US\$1.00 million (or approximately HK\$7.80 million) and approximately US\$3.36 million (or approximately HK\$26.21 million), respectively, in respect of the Company’s equity portfolio of financial assets at fair value through profit or loss for the Reporting Period (Corresponding Period: approximately nil and gain of US\$12.18 million (or approximately HK\$95.00 million) respectively); and
- ii) no milestone payment being received during the Reporting Period, while in the Corresponding Period, the Group received a milestone payment of US\$3.20 million (or approximately HK\$24.96 million) (before withholding tax) from Wanbang Biopharmaceutical Co., Ltd., the Company’s commercial strategic partner for China, on 31 March 2021 in respect of obtaining clinical trial approval from the Centre of Drug Evaluation in China on 5 February 2021.

All other items making up the loss for the Reporting Period were similar to those for the Corresponding Period.

The Company is in the process of finalising the interim results of the Group for the Reporting Period. The information contained in this announcement is only based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the Reporting Period and the information currently available, which has not yet been finalised nor reviewed by the Company's auditors or the Audit Committee of the Company, and therefore may be subject to adjustments. Shareholders and potential investors of the Company are advised to refer to the announcement of the unaudited consolidated interim results of the Group for the Reporting Period, which is expected to be published by end of August 2022.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

Note: Unless otherwise specified herein, the amounts dominated into US\$ have been translated, for the purpose of illustration only, into HK\$ using the exchange rate of US\$1.00 = HK\$7.80.

By Order of the Board
Endurance RP Limited
Jamie Gibson
Executive Director

Hong Kong, 22 July 2022

As at the date of this announcement, the Board comprises six Directors:

Executive Director:

Jamie Gibson (*Chief Executive Officer*)

Non-Executive Directors:

James Mellon (*Chairman*)

Jayne Sutcliffe

Independent Non-Executive Directors:

David Comba

Julie Oates

Mark Searle

* For identification purposes only